Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04137822 | Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer | no longer available | — | — | Impatients N.V. trading as myTomorrowsINDUSTRY | 2 | Aug 14, 2020 | clinicaltrials |
| NCT02174679 | 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 |
| NCT02826395 | C11 Sodium Acetate PET/CT Imaging of PCa | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02531672 | Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography | no longer available | — | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT03702036 | Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma | no longer available | — | — | GlaxoSmithKlineINDUSTRY | 0 | Apr 13, 2020 | clinicaltrials |
| NCT02568943 | An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 6 | Apr 8, 2020 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT03460782 | An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas | no longer available | — | — | Center Trials & TreatmentOTHER | 8 | Nov 8, 2019 | clinicaltrials |
| NCT02297529 | Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma | no longer available | — | — | AmgenINDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03723057 | Expanded Access for AG-221 | no longer available | — | — | CelgeneINDUSTRY | 1 | Oct 24, 2019 | clinicaltrials |
| NCT02715843 | Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | no longer available | — | — | Molecular Templates, Inc.INDUSTRY | 1 | Oct 11, 2019 | clinicaltrials |
| NCT03503890 | Expanded Access to Rovalpituzumab Tesirine | no longer available | — | — | AbbVieINDUSTRY | 0 | Sep 10, 2019 | clinicaltrials |
| NCT03492489 | Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma | no longer available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Aug 1, 2019 | clinicaltrials |
| NCT03123952 | Expanded Access to ABT-414 | no longer available | — | — | AbbVieINDUSTRY | 0 | Jul 15, 2019 | clinicaltrials |
| NCT03029481 | Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 0 | Mar 28, 2019 | clinicaltrials |
| NCT03529539 | Expanded Access for PSV Personalized Oncolytic Viruses(PSV) | no longer available | — | — | EpicentRx, Inc.INDUSTRY | 0 | Mar 6, 2019 | clinicaltrials |
| NCT03850704 | Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | no longer available | — | — | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 22, 2019 | clinicaltrials |
| NCT03723096 | Expanded Access for CC-4047 | no longer available | — | — | CelgeneINDUSTRY | 1 | Dec 20, 2018 | clinicaltrials |
| NCT02547675 | Rociletinib (CO-1686) USA Expanded Access Program | no longer available | — | — | Clovis Oncology, Inc.INDUSTRY | 1 | Sep 25, 2018 | clinicaltrials |
| NCT03409081 | Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | no longer available | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 13, 2018 | clinicaltrials |
| NCT02564224 | Study Comparing Pursestring Wound Closure vs Conventional Closure to Reverse Stoma of Colorectal Cancer Patients(PURSE) | no longer available | — | — | Zhejiang UniversityOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01777061 | Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan | no longer available | — | — | Wendell Yap, MDOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT03005262 | MLN8237 for a Subject With Adenocarcinoma of the Prostate | no longer available | — | — | The University of Texas Health Science Center at San AntonioOTHER | 0 | Apr 4, 2018 | clinicaltrials |
| NCT02784158 | An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | no longer available | — | — | Ariad PharmaceuticalsINDUSTRY | 1 | Feb 6, 2018 | clinicaltrials |
| NCT02083484 | Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) | no longer available | — | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 26, 2018 | clinicaltrials |
| NCT03311542 | Expanded Access for Pembrolizumab (MK-3475) | no longer available | — | — | Center Trials & TreatmentOTHER | 4 | Jan 10, 2018 | clinicaltrials |
| NCT03068650 | Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut(CDX-110) | no longer available | — | — | Celldex TherapeuticsINDUSTRY | 0 | Oct 18, 2017 | clinicaltrials |
| NCT00210665 | A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 3 | Oct 10, 2017 | clinicaltrials |
| NCT02666209 | Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | no longer available | — | — | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2017 | clinicaltrials |
| NCT00701168 | Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer | no longer available | — | — | Leo W. Jenkins Cancer CenterOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT01980732 | 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors | no longer available | — | — | Andrei IagaruOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02416232 | Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma | no longer available | — | — | GlaxoSmithKlineINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT02473653 | Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive Metastatic Cancer | no longer available | — | — | University of PennsylvaniaOTHER | 1 | Aug 11, 2017 | clinicaltrials |
| NCT02824094 | Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC | no longer available | — | — | PfizerINDUSTRY | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01956253 | Single Subject Neratinib in Bladder Cancer (NRR) | no longer available | — | — | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 14, 2017 | clinicaltrials |
| NCT00589030 | Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | no longer available | — | — | City of Hope Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01120561 | A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer | no longer available | — | — | Genentech, Inc.INDUSTRY | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02186249 | Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma(CheckMate218) | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 2 | Feb 8, 2017 | clinicaltrials |
| NCT02375464 | Gallium-68 DOTATOC for Management of Neuroendocrine Tumors | no longer available | — | — | Northwell HealthOTHER | 0 | Nov 8, 2016 | clinicaltrials |
| NCT02358018 | 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial | no longer available | — | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02712567 | SARC021C: A Continuation Study of TH-CR-406/SARC021 | no longer available | — | — | Sarcoma Alliance for Research through CollaborationOTHER | 0 | Oct 13, 2016 | clinicaltrials |
| NCT02755987 | Expanded Access to ANG1005 for Individual Patients | no longer available | — | — | Angiochem IncINDUSTRY | 1 | Jun 7, 2016 | clinicaltrials |
| NCT02147951 | Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma | no longer available | — | — | AmgenINDUSTRY | 1 | Mar 1, 2016 | clinicaltrials |
| NCT00423826 | Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease | no longer available | — | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT02204553 | Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00799539 | A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients | no longer available | — | — | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Dec 2, 2015 | clinicaltrials |
| NCT00999414 | UARK 2009-32 Compassionate Use Study of Carfilzomib(2009-32) | no longer available | — | — | University of ArkansasOTHER | 1 | Oct 26, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Aug 14, 2020source: clinicaltrials